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Abstract
We conducted studies in Vanuatu to evaluate potential screening and treatment strategies to assist with control of cervical
cancer. In a pilot study of 496 women, visual inspection and cytology were evaluated as screening tests for detection of CIN
2 or worse (CIN2+), observed in 21 of 206 subjects biopsied on the basis of abnormal visual inspection or cytology.
Sensitivity of visual inspection with Lugol’s Iodine for detection of CIN2+ on biopsy was 0.63, specificity was 0.32, and the
positive predictive value was 0.09. For HSIL cytology, sensitivity was 0.99, specificity was 0.77, and the positive predictive
value was 0.88. HSIL cytology was significantly more sensitive and had a significantly higher PPV for CIN 2+ than visual
inspection (p,0.01). In a further study of 514 women, we compared testing for HR HPV and cytology as predictors of biopsy
proven CIN 2+. Sensitivity of HSIL cytology for CIN2+ as established by loop excision of the cervix was 0.81, specificity was
0.94, and positive predictive value was 0.48. Sensitivity of a positive test for HR HPV for detection of CIN2+ was non-
significantly different from cytology at 0.81, specificity was 0.94, and positive predictive value was 0.42. Combining the two
tests gave a significantly lower sensitivity of 0.63, a specificity of 0.98, and a positive predictive value of 0.68. For women
over 30 in a low resource setting without access to cytology, a single locally conduced test for high risk HPV with effective
intervention could reduce cervical cancer risk as effectively as intervention based on cytology conducted in an accredited
laboratory.
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Introduction
Cervical cancer is a disease of the developing world, and is
responsible for over 250,000 deaths annually. Cytological screening
programs can be effective for prevention of cervical cancer in the
developed world, but rely heavily on effective cytopathology
services and call/recall systems to ensure compliance with regular
screening assessments amongst at risk women [1]. Neither of these
criteria can currently be met in resource poor settings [2].
To overcome this problem, alternate strategies have been
proposed to detect women in low resource settings requiring
intervention to prevent cervical cancer. These include visual
inspection of the cervix [3] by trained nurse practitioners, with
staining enhanced by Lugols Iodine (VILI) or Acetic Acid (VIA) [4]
and, more recently, testing for infection of the genital tract with high
risk human papillomaviruses(HR HPV) [5], as persisting infection of
the cervix with these viruses is responsible for over 98% of cervical
cancer. There have been varying reports of the efficacy of these
assays for detection of lesions requiring intervention [6–8], and there
has also been debate about what should comprise definitive
treatmentforcervicalcancerpreventioninalowresource setting[9].
Vanuatu is a Pacific island nation with limited health care
facilities and a poorly documented incidence of cervical cancer,
believed similar to the high rates reported for the neighbouring
country of Fiji [10]. At the time of study there were no measures in
place to prevent cervical cancer and minimal facility to treat
disease if detected. As part of a government supported program to
investigate approaches to prevention of cervical cancer through
vaccination and screening, we evaluated the prevalence of HR
HPV infection and of cervical pre-cancer, and the efficacy of
possible screening and treatment strategies, in apparently healthy




A pilot study recruited female subjects aged between 30 and 50
in 2006 by poster and flier advertisement, radio publicity, and
nurse ‘‘awareness’’ visits to villages round Port Vila, Efate Island,
Vanuatu. Women with a history of gynaecological surgery were
excluded. Informed consent was obtained from all participants. A
follow on study used a similar recruitment strategy in 2008
amongst non-participants in the first study, and 519 further
subjects were recruited. The studies were approved by the Human
Experimentation Ethics Committee of the University of Queens-
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conducted in accordance with the principles expressed in the
Declaration of Helsinki. Written informed consent was obtained
from all participants. Where necessary this was supplemented by
verbal consent in an appropriate language for the participant. The
studies are registered in the Australian and New Zealand Clinical
Trials Registry (Registration No ACTRN12610000702011).
Assessment
For the pilot study (Figure 1a), a brief medical history and
physical examination for hypertension, obesity, visual acuity and
diabetes was undertaken. Women underwent a direct light
unmagnified speculum examination of the cervix after exposure
of the cervix to Acetic Acid (VIA) and again after exposure to
Lugols Iodine (VILI). The cervical appearance was reported as
within normal limits or significantly abnormal by nursing staff
trained and evaluated according to the IARC training manual
[11], and, independently, by one of a panel of experienced
gynaecologists who were not informed of the findings from the
nurse examination. Cervical samples were collected for Pap smear
and HPV DNA testing prior to application of Acetic Acid. All
women subsequently underwent colposcope aided examination of
the cervix by an experienced gynaecologist. Women with any
visible abnormality of the cervix or an abnormal pap smear had a
colposcopically directed biopsy. Those with local (one or 2
quadrant) cervical disease were then treated by cryotherapy, and
those with more extensive disease were referred for loop
electrosurgical excision of the cervix transition zone (LLETZ),
conducted under local anaesthesia at the Port Vila Hospital. In a
second study (Figure 1b), a cervical sample for a Pap smear and
HR HPV testing was collected from all recruited subjects. All
women testing positive for HR HPV, or with a cytological
diagnosis of possible HSIL or worse (Australian classification
system), were invited to return for LLETZ.
Pathology
Cervical cytology samples were taken using a cytobrush and a
Cervex sampler, and were processed for both slide and liquid
based cytology and for HR HPV DNA testing (Digene HC2 High-
Risk HPV DNA Test from QIAGEN). For the first study, samples
Figure 1. Flow charts for subject recruitment and investigation.
doi:10.1371/journal.pone.0013266.g001
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for gonorrhoea (2 positive of 492 valid samples) and subjects were
also tested for HIV-1 serology (no confirmed positives). Biopsies
and LLETZ specimens were fixed in neutral buffered formalin for
transportation to Australia. All cytology and histology examina-
tions were conducted by accredited Australian diagnostic pathol-
ogy providers participating in National Association of Testing
Laboratories (NATA) approved quality control and quality
assurance schemes for cervical cytology and pathology, and
blinded to the clinical and HPV findings. For the pilot study, HPV
DNA testing was performed according to the manufacturer’s
instructions in Australia by a NATA approved laboratory, and for
the subsequent study, locally by a trained nurse technician.
Statistical Analysis. Statistical analysis was performed using
appropriate modules of Statistica V9 (Statsoft, Tulsa, Oklahoma).
Results
Apparently healthy Ni-Vanuatu women age 30–50 were
recruited to a study to evaluate possible strategies for cervical
cancer screening. Amongst a study cohort of 499 women (mean
age 39.3y 65.9y), clinically evident cervical cancer was confirmed
on biopsy in five subjects who were not included further in the
analysis. The remaining women were examined for visual
abnormalities of the cervix, by VIA and VILI without magnifi-
cation, independently by a gynaecologist and a trained nurse, and
subsequently colposcopically by a gynaecologist. They were also
tested for cytological abnormalities of the cervix using liquid based
cytology. If any test were abnormal, subjects underwent
colposcopically directed biopsy of the cervix, or LLETZ excision
if cancer was suspected clinically. Of 494 subjects evaluated, 206
were biopsied, and 21 were found at biopsy to have CIN 2+.
Correlation between VIA and VILI findings, and between visual
inspection findings by doctor and by nurse, was only moderate
(Table 1). Amongst 278 subjects with normal visual inspection by all
modalities (Table 2), 263 subjects also had normal cervical cytology,
of whom a non-random sample of 15 were biopsied with no CIN 2+
detected,and15 subjectshad abnormalcervical cytology (9HSIL, 6
LSIL) of whom 8 had CIN2+ on biopsy (7 HSIL, 1LSIL). Amongst
214 subjects with abnormal visual inspection by at least one
modality, 38 were not biopsied because cytology was normal and at
subsequent colposcopy the cervix appearednormal. Of the176with
abnormal cytology or colposcopic appearance, 12 had biopsy
proven CIN 2+. Apparent sensitivity of visual inspection (VILI) for
detection of CIN2+ on biopsy was0.63, specificity was 0.32, and the
positive predictive value was 0.09. Overall, cervical cytology was
abnormal in 32 of 474 women with technically satisfactory samples
(LSIL 13, HSIL 19), and identified 15 of 21 women found to have
CIN 2+ on biopsy (1 LSIL, 14 HISL). HSIL cytology had a
sensitivity for detection of CIN2+ of 0.99, specificity was 0.77, and
the positive predictive value was 0.88.
Most subjects in this study were also tested for high risk (HR)
HPV using the liquid based cytology specimen. Of 488 subjects
tested for high risk HPV, 44 were positive. A similar rate of
positive HPV tests was observed in each 5 year age cohort (30-35y
(n=156), 10.2%; 36-40y (n=139), 7.9%; 41-45y (n=99); 12.1%;
46-50y (n=95), 8.4%). Of the 44 subjects with a positive HPV test,
9 had normal visual inspection and cytology: two of these
Table 1
Nurse VILI result
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Bx* Specificity Sensitivity PPV NPV
VIA Nurse 10 92 14 9 84 277 0.48 (0.40–0.55) 0.53 (0.23–0.75) 0.10 (0.05–0.17) 0.90 (0.82–0.95)
Doctor 10 80 9 9 96 282 0.55 (0.47–0.62) 0.53 (0.29–0.75) 0.11 (0.06–0.20) 0.91 (0.84–0.96)
VILI Nurse 11 122 20 8 54 270 0.33 (0.26–0.40) 0.58 (0.34–0.79) 0.09 (0.05–0.15) 0.87 (.76–0.94)
Doctor 12 120 15 7 56 271 0.32 (0.25–0.39) 0.63 (0.39–0.83) 0.09 (0.05–0.16) 0.89 (0.78–0.95)
Colposcopy 9 23 1 12 150 284 0.87 (0.81–0.91) 0.43 (0.23–0.66) 0.28 (0.14–0.47) 0.93 (0.87–0.96)
HPV DNA 14 18 16 7 162 274 0.90 (0.85–0.94) 0.67 (043–0.85) 0.44 (0.27–0.62) 0.96 (0.91–0.98)
Cytology LSIL+ 16 11 3 5 160 286 0.94 (0.88–0.97) 0.76 (0.52–0.91) 0.59 (0.39–0.77) 0.97 (0.93–0.99)
HSIL+ 15 2 2 6 167 287 0.99 (0.95–1.00) 0.71 (0.48–0.88) 0.88 (0.62–0.98) 0.97 (0.92–0.99)
*, If visual inspection was the only abnormal test at the primary visit, and the cervix was visually normal at the biopsy visit, no biopsy was taken.
@ Specificity and PPV for CIN2+: VIA and VILI were significantly less sensitive and less predictive than HPV DNA, LSIL or HSIL (sensitivity p,0.01 in each case; PPV p,0.05
for LSIL, p,0.01 for HSIL). Sensitivity and NPVs were not significantly different between any of the tests.
doi:10.1371/journal.pone.0013266.t002
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positive HPV test and either abnormal cytology or abnormal
visual inspection, and therefore subjected to biopsy, 14 had biopsy
proven CIN 2+. Normal cytology, if used to triage those with
positive HPV tests, would have excluded 12 subjects without CIN
2+ from biopsy, and none with CIN 2+. Of 163 women with
normal cytology and a negative HPV test who were subject to
biopsy because of abnormal visual inspection, 5 had CIN 2+ on
directed biopsy. However, on subsequent LLETZ excision, none
had CIN 2+ identified within the pathology specimen.
On specific questioning, a history of post coital or inter-menstrual
bleeding was elicited from one of 5 subjects with invasive cancer,
none of 21 with biopsy proven CIN 2+, 13 of 182 with normal or
low grade pathology on biopsy, and 18 of 291 subjects for whom no
biopsy was taken. Thus, elicited symptoms were of no predictive
value for selecting women for further screening.
Of 21 subjects from this study with CIN 2+ on biopsy, 15 were
predicted by HSIL cytology, of whom 14 also had HR HPV. No
subject had CIN2+ predicted only by HR HPV, and the 5 who
were detected only by abnormal VIA/VILI were not confirmed
on LLETZ excision. Overall, 6 of 21 biopsy identified CIN2+
lesions would have been missed in this study if possible HSIL or
worse cytology or a positive test for HR HPV had been used as the
screening tests without regard to cervical appearance.
We were aware of the possible ascertainment bias inherent in
the first study, in which cytology results, but not HR HPV test
results, were used to determine collection of a biopsy in the
absence of visual abnormality. The number of women with HR
HPV but with normal inspection and cytology, and therefore not
subjected to biopsy, and therefore the maximum error in true case
ascertainment, was 7, or 25% of subjects with actual or potential
CIN2+. We therefore undertook a further study in a new cohort of
women drawn from the same population. Women between 30 and
50 (n=512; Mean age 38.36 SD 5.6) were recruited using the
same strategy as for the first study, and tested for abnormal
cytology, defined as possible HSIL or worse, and for HR HPV on
the same specimen. If either test were abnormal (n=77), LLETZ
excision was offered (Table 3). Of 74 subjects consenting subjects,
27 had CIN 2+ confirmed in the LLETZ specimen. No immediate
complications of LLETZ were observed. HSIL cytology (n=49;
mean age 38.3) or a positive HR HPV test (n=54; Mean age 36.5)
were equally sensitive predictors of high grade cervical pathology
detected on LLETZ excision, with cytology slightly more specific
(Table 4). If abnormality of both tests were set as the screening
criterion, the specificity for high grade cervical pathology was
better but the sensitivity was significantly less.
Discussion
In this study we show that cervical cancer is common amongst
unscreened apparently healthy Ni-Vanuatu women over 30, with a
point prevalence estimate of approximately 100/10
5 women.
Cervical pre-cancer is also common in this population with a point
prevalence of about 500/10
5 women. Biopsy proven CIN 2+ in over
30 year old women is a reliable predictor of lifetime risk of
development of cervical cancer [12], as evidenced by its mandatory
treatment and follow up in most countries with screening programs,
and was therefore used as the gold standard to evaluate possible
screening tests in the present study. While histological distinction of
CIN2 from CIN3 remains controversial, and CIN2 in younger
women is common and of uncertain significance, CIN2 in older
women is a marker of HR HPV infection which commonly
progressesinthisagegrouptoCIN3[13].BiopsydiagnosedCIN2or
worse, as determined in an accredited pathology laboratory in
Australia, is regarded as of high predictive value for future develop
ment of cervical cancer and mandates surgical treatment [14].
To reduce the cervical cancer burden in a low resource setting,
a single screening test for women over 30 years of age has been
Table 3. Pathology associated with abnormal HPV test and
cytology findings in study 2.
LLETZ Pathology





benign 359 0 0 0 359
LSIL 20 00 0 2 0
HSIL 23 57 9 2
unsatisfactory 57 00 0 5 7
Positive
(n=53)
benign 20 31 0 6 1
LSIL 5 13 1 0
HSIL 26 17 5 3 1




benign 6 00 0 6
LSIL 0 00 0 0
HSIL 0 00 0 0
unsatisfactory 1 00 0 1
doi:10.1371/journal.pone.0013266.t003
Table 4. Sensitivity and specificity of HPV testing and Cytology for CIN2+ at LLETZ in study 2.









2+ CIN1 Normal Specificity Sensitivity NPV PPV
HR HPV+ve or Cyto HSIL 518 77 4 27 25 21 0.91 (0.88–0.93) 1.00 (0.84–1) 1.00 (0.99–1) 0.37 (0.26–0.49)
HR HPV +ve 512 54 2 22 18 12 0.94 (0.91–0.95) 0.81 (0.61–0.93) 0.99 (0.97–1.00) 0.42 (0.29–0.57)
Cyto HSIL 458 49 3 22 12 12 0.94 (0.92–0.96) 0.81 (0.61–0.93) 0.99 (0.97–1.00) 0.48 (0.33–0.63)
HR HPV+ and Cyto HSIL 453 26 1 17 5 3 0.98 (0.96–0.99) 0.63 (0.42–0.80) 0.98 (0.96–0.99) 0.68 (0.46–0.84)
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false negative rate for significant cervical pathology, as subse-
quently detected by colposcopically directed biopsy, as was
demonstrated in the current study. Colposcopically directed biopsy
can be supplemented by multiple biopsies [15], and is sometimes
proposed as a gold standard for assessing cervical pathology in
epidemiological studies, but can miss significant pathology [16],
particularly within the cervical canal. We chose in the initial study to
limit biopsy to women with visual abnormalities or positive cytology,
which resulted in 41% of women proceeding to biopsy. We
confirmed in a small non-random subset that women with normal
visualinspectionandnormalcytologyhadalowprevalenceofbiopsy
detected pathology. They also had a low prevalence (7 of 278; 2.5%)
of high risk HPV infection, with over 95% sampled for HR HPV.
The predictive value of a negative HPV testfor absence of pathology
amongst women with no cytological abnormalities has recently been
reported in a more controlled study (ATHENA) as over 95%. Thus
the ascertainment bias in the current study attributable to a policy of
not taking a biopsy from the majority of women with normal visual
inspection and cytology is likely to be small.
A study of 500 women, even in a country with a high prevalence
of disease, has limited power to compare sensitivity and specificity
of the various tests. However, visual inspection of the cervix,
assisted by acetic acid or Lugols iodine staining, identified 43% of
all women in the current study as having significant abnormalities
in need of further investigation, a figure significantly higher than
the prevalence of disease requiring treatment. The high prevalence
of visual abnormalities that would then require treatment, and
their relatively poor sensitivity and specificity for high grade
premalignant lesions would make visual inspection a poor choice
as a feasible single test approach to cervical cancer screening in
this population. Thus this study lends support in another
geographical setting to the conclusion from a recent report that
in India treatment of abnormalities identified through visual
inspection is not, in contrast to HPV testing, a practical means of
reducing the risk of death from cervical cancer[17].
The high frequency of observed visual abnormality in the
current study contrasts with the findings of a meta-analysis of over
52,000 subjects participating in similar studies in which 17% of
subjects had abnormal visual inspection. In the meta-analysis,
about half the rate of CIN 2+ observed in the current study was
reported (2.3% cf 4.2%) [6]. This significant difference may reflect
differences in inspection classification, or alternatively a higher
prevalence of HPV infection, as suggested by the greater CIN2+
rate, or of intercurrent bacterial and chlamydial infections
resulting in abnormality on visual inspection.
The better sensitivity and specificity of cytology for detecting
CIN2+ in the current study when compared with the meta-
analysis might reasonably be attributed to the use of highly
experienced cytology laboratory [18]. In our current study, a
significant number of subjects, (7 of 21 in the pilot study and 5 of
27 in the definitive study) had a negative test for HR HPV despite
abnormal cytology and biopsy proven CIN 2+. These results are
consistent with the meta-analysis, in which HC2 demonstrated a
sensitivity of 0.62 and a specificity of 0.93 for detection of CIN2+.
However, these figures are at odds with the generally accepted
90% sensitivity of HR HPV testing for biopsy proven CIN 2+
disease in similarly aged cohorts in published studies in the
developed world. As the HPV-ve samples that subsequently were
shown to come from women with biopsy established cervical
pathology in our study demonstrated HSIL on cytology of the
same sample, collection of an inadequate sample seems unlikely.
Sub-optimal sample handling after collection, under field condi-
tions where samples are exposed to heat and adverse storage
conditions and times, might explain loss of HPV assay sensitivity.
This needs further evaluation.
Our second study was performed to define the relative utility of
abnormal cytology and/or HPV test findings as a screen for CIN
2+, and to establish more precisely the nature of cervical pathology
present than was possible by directed biopsy. Relative sensitivity
and specificity of HC2 HPV detection for incident CIN 2+ was
similar in our two studies, and, consistent with removal of possible
ascertainment bias inherent in the first study design, the sensitivity
of cytology was somewhat lower.
HC2 HPV detection is somewhat less specific and considerably
more sensitive than cytology for detection of CIN2+ lesions in
populations preselected by a prior abnormal pap smear[19], and
the specificity increases with increasing subject age[20]. The
prevalence of high grade lesions amongst those with a positive HR
HPV test in the current study approximates 40%. A recommen-
dation was voiced recently for management of patients with a
screening test suggestive of cervical pathology (Mark Stoler,
International Papillomavirus Workshop, Montreal 2010 – www.
hpv2010.org) that where routine colposcopy and biopsy services
are available, screening findings with a .40% probability of an
underlying high grade cervical lesion should be treated definitively,
and those with less should be further assessed. Cryotherapy of
visual abnormalities of the cervix has been proposed as a strategy
for prevention of progression of CIN2+ to cancer but is not
recommended by WHO for large lesions, or lesions within the
cervical canal, which are more likely to persist and to progress to
cancer [21–23] and were common in our current study where 91
of 176 women with visual abnormalities were deemed suitable for
cryotherapy, and only 2 of the women suitable for cryotherapy
had CIN 2+ on biopsy, representing less than 10% of the subjects
with CIN 2+. In a resource poor setting, loop excision of the
transformation zone can be safely undertaken in hospital by
trained health care practitioners [24], greatly increasing its utility
as a cancer control measure. While an optimal screening strategy
for cervical cancer prevention might involve primary screening by
HPV DNA and subsequent cytology, our data suggest that this
strategy would need to involve multiple cytology tests to ensure
detection of the majority of CIN2+ lesions associated with a
positive HR HPV results. Further, it has been argued that any
positive HR HPV test in women over 30y is indicative of a chronic
HPV infection, which conveys a significant life time risk of
development of cervical cancer even in women without currently
apparent cytological abnormalities [25]. Where a cytology triage is
not possible, loop excision of the cervix for those testing positive
for HR HPV is a feasible strategy for control of cervical cancer,
and is likely to remove HPV associated pathology completely in over
90% of patients [9]. The ongoing efficacy of a program based on
LLETZ excision of cervical pathology could be evaluated through
submission of a random sample of excised material for pathological
review in a developed country, to ensure that the expected rate of
detection of CIN2+ is being achieved in excised material.
We propose from our findings that a single low cost HPV test, as
currently being developed by PATH in cooperation with
QIAGEN and the Gates Foundation, with loop excision of the
cervix for those with a positive test who have completed their
reproductive plan, would be the most appropriate approach to
cervical cancer reduction in resource poor countries with high
disease prevalence.
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